Homologous recombination (gene targeting) has many desirable features for gene therapy, because it can precisely correct mutant genes and restore their normal expression, and random nonhomologous integration of DNA is infrequent in cells in which homologous recombination has occurred. There are, however, no reports of attempts to use homologous recombination to correct mutant genes in normal hematopoietic stem cells (HSCs), which are prime cells for therapy of a variety of hematological and other conditions, presumably because of their low abundance and uncertainty that homologous recombination can occur at a usable frequency in these cells. The experiments reported here encourage optimism in this respect by demonstrating targeted correction of a defective hypoxanthine phosphoribosyltransferase gene in hematopoietic progenitor cells that can form colonies in methylcellulose culture. These clonogenic cells are in the same lineage as HSCs but are more abundant and more mature and so less pluripotent. T he ideal form of gene therapy would correct a mutant gene directly without causing changes elsewhere in the genome (1). Many of the problems associated with gene therapy would thereby be greatly reduced or eliminated, including lack of adequate expression, extinction of expression, and the mutagenesis associated with integrating the correcting sequences into random sites in the genome. Homologous recombination has the necessary prerequisites for use in this context, because it is capable of precisely correcting mutant genes (2), and random nonhomologous integration of targeting DNA into the genome is infrequent in cells in which homologous recombination has occurred (3). However, we find no reported attempts of using homologous recombination to correct mutant genes in normal hematopoietic stem cells (HSCs; ref. 4), which are prime cells for therapy of a variety of hematological and other conditions (5). The likely reasons appear to be the low abundance of these cells combined with uncertainty that homologous recombination can occur in them at a usable frequency. The experiments we report here were designed to test the possibility of using homologous recombination to correct a mutant gene in hematopoietic progenitor cells that can form colonies in tissue culture. These colony-forming cells (CFCs) are in the same lineage as HSCs but are more abundant and more mature, and therefore less pluripotent. We demonstrate that the hypoxanthine phosphoribosyltransferase (HPRT) gene, which is mutated in humans with Lesch-Nyhan disease (6, 7), can be corrected by homologous recombination in CFCs at frequencies equivalent to those seen in embryonic stem (ES) cells, encouraging optimism that homologous recombination to correct mutant genes in pluripotent stem cells capable of long-term hematopoietic repopulation eventually will prove feasible. . The mixtures were plated in standard methylcellulose medium (MethoCult GF M3434; StemCell Technologies, Vancouver) containing the following recombinant cytokines: mouse stem cell factor (50 ng/ ml)͞mouse IL-3 (10 ng/ml)͞human IL-6 (10 ng/ml)͞human erythropoietin (3 units/ml)͞bovine pancreatic insulin (10 g/ ml). Selection was with HAT (120 M hypoxanthine/0.4 M aminopterin/20 M thymidine). Colonies were counted under dark-field illumination at day 14.
T
he ideal form of gene therapy would correct a mutant gene directly without causing changes elsewhere in the genome (1) . Many of the problems associated with gene therapy would thereby be greatly reduced or eliminated, including lack of adequate expression, extinction of expression, and the mutagenesis associated with integrating the correcting sequences into random sites in the genome. Homologous recombination has the necessary prerequisites for use in this context, because it is capable of precisely correcting mutant genes (2) , and random nonhomologous integration of targeting DNA into the genome is infrequent in cells in which homologous recombination has occurred (3). However, we find no reported attempts of using homologous recombination to correct mutant genes in normal hematopoietic stem cells (HSCs; ref. 4) , which are prime cells for therapy of a variety of hematological and other conditions (5) . The likely reasons appear to be the low abundance of these cells combined with uncertainty that homologous recombination can occur in them at a usable frequency. The experiments we report here were designed to test the possibility of using homologous recombination to correct a mutant gene in hematopoietic progenitor cells that can form colonies in tissue culture. These colony-forming cells (CFCs) are in the same lineage as HSCs but are more abundant and more mature, and therefore less pluripotent. We demonstrate that the hypoxanthine phosphoribosyltransferase (HPRT) gene, which is mutated in humans with Lesch-Nyhan disease (6, 7), can be corrected by homologous recombination in CFCs at frequencies equivalent to those seen in embryonic stem (ES) cells, encouraging optimism that homologous recombination to correct mutant genes in pluripotent stem cells capable of long-term hematopoietic repopulation eventually will prove feasible. . The mixtures were plated in standard methylcellulose medium (MethoCult GF M3434; StemCell Technologies, Vancouver) containing the following recombinant cytokines: mouse stem cell factor (50 ng/ ml)͞mouse IL-3 (10 ng/ml)͞human IL-6 (10 ng/ml)͞human erythropoietin (3 units/ml)͞bovine pancreatic insulin (10 g/ ml). Selection was with HAT (120 M hypoxanthine/0.4 M aminopterin/20 M thymidine). Colonies were counted under dark-field illumination at day 14.
Materials and Methods
Electroporation. Electroporations were performed with a cuvette having a gap size of 4 mm and an area of 160 mm 2 (BTX, San Diego) with a 1-s pulse from a 250 F capacitator charged to 300 V. BM and ES cells were suspended at a density of 0.3-1.5 ϫ 10 8 cells/ml in conventional ES-cell medium (10, 11) , containing DMEM with 15% heat-inactivated FBS and 10 M 2-mercaptoethanol. Linearized correcting DNA was 1.6-5 nM. After electroporation at room temperature, the cell suspensions were held at room temperature for 5-10 min before plating.
Correcting DNA Plasmid. The MP8neo plasmid used for preparing correcting DNA has a copy of the pMC1neo gene (not used in these experiments) between the 5Ј homologous region and the promoter region of the MP8 plasmid described (ref. 3; Fig. 1C ). The MP8neo plasmid DNA was linearized with BamHI before use.
Selection of HAT-Resistant Colonies. BM cells were flushed from the femur and tibia by using DMEM with 10% heat-inactivated FBS and made into a single-cell suspension by repeated passage through an 18-gauge needle; 5-10 ϫ 10 7 BM cells from individual male mice were electroporated in 0.5-0.8 ml of medium and plated in 35-mm dishes (1 ml per dish) after mixing with 10 ml of methylcellulose culture medium (MethoCult GF M3434; StemCell Technologies). Cell numbers did not exceed 1 ϫ 10 7 /ml. One milliliter of twice final concentration HAT (2ϫ ϭ 240 M hypoxanthine/0.8 M aminopterin/40 M thymidine) was added along the wall to each dish of cells 2 days after electroporation. These conditions support the growth of HATresistant clonogenic progenitor cells. The input numbers of CFCs were determined by culturing 5 ϫ 10 4 BM cells in 1 ml of the same methylcellulose medium without HAT. Colonies were counted under dark-field illumination at day 14. The procedure used for gene targeting in ES cells was essentially as described (10) except that HAT selection was imposed 2 days after electroporation.
Reverse Transcription-PCR (RT-PCR) Analyses and Sequencing of Transcripts. HAT-resistant colonies were picked under a dissecting microscope and washed with 200 l of cold PBS. Preparation of RNA and cDNA synthesis using an oligo(dT) primer were with a Cells-to-cDNA kit supplied by Ambion (Austin, TX). PCR conditions were: 94°C for 2 min, then 35 cycles of 94°C for 30 s, 58°C for 1 min, and 72°C for 1 min. The primers were 5Ј-TCCTCCTCCTGAGCAGTCAG-3Ј (for human exon 1), and 5Ј-ATCTCCACCAATAACTTTTATGTCCC-3Ј (for mouse exon 4). The expected PCR product was 402 bp. The quality of the tested RNA was confirmed by PCR with primers specific for the murine glyceraldehyde-3-phosphate dehydrogenase gene, 5Ј-GTTCCAGTATGACTCCACTCACG-3Ј and 5Ј-AGATC-CACGACGGACACATTG-3Ј, which gives a 597-bp fragment. PCR products were electrophoresed in 2% agarose gel and stained with ethidium bromide. The 402-bp PCR product was isolated and purified by QIAquick (Qiagen, Chatsworth, CA) and sequenced by using an automatic DNA sequencer (Applied Biosystems).
Results
To establish conditions able to detect homologous recombination events in a clonogenic assay, we first carried out reconstruction experiments with mixtures of wild-type and mutant BM cells. BM cells were prepared from male mice having a partial deletion of the X-linked Hprt gene; these Hprt Ϫ cells are killed by HAT-containing medium. We also prepared BM cells from wild-type mice having a functional Hprt gene; these Hprt ϩ cells survive in HAT-containing medium. Mixtures were made with decreasing numbers of wild-type Hprt Fig. 1 A shows that this does not affect the colony count.
Our procedure for assaying homologous recombination in hematopoietic colony-forming progenitors is illustrated in Fig. 1 B and C. BM cells are isolated from descendants of mice originally generated by Hooper et al. (8) from an ES cell that is Hprt Ϫ as a consequence of a spontaneous 55-kb deletion (12) that includes the promoter and exons 1 and 2 of the Hprt gene. The correcting DNA, which has Ϸ6 kb of its sequence homologous to the target locus, supplies the missing promoter and exons after homologous recombination (Fig. 1C) . We introduce correcting DNA into the Hprt Table 1 . In the first two experiments, the input numbers of CFCs were calculated on the assumption that 10 Ϫ5 BM cells contain 200 CFCs, a figure derived from the data in Fig.  1 A, which were obtained with BM cells from mice of a similar age. In the remaining four experiments, the input numbers of CFCs were directly assayed by counting colonies formed in the absence of HAT selection and without electroporation. The frequency of gene correction ranged from 1.2 to 9.2 per 10 5 input CFCs, with a mean and standard deviation of 4.4 Ϯ 3.3 ϫ 10 Ϫ5 . This frequency is a conservative estimate, because no corrections were made for cells killed by the electroporation. One experiment failed to yield any HAT-resistant colonies, but this result is not unexpected statistically because the input number of CFCs in this BM sample was low (0.3 ϫ 10 5 ).
The HAT-resistant colonies derived from Hprt Ϫ BM cells after gene correction were indistinguishable in gross appearance from the colonies derived from wild-type BM cells cultured in the presence of a comparable excess (Ͼ100ϫ) of Hprt Ϫ BM cells ( Fig. 2A Left) . The types of cell present in the wild-type and corrected colonies, as judged from cytospin preparations (Fig.  2 A Right) , were likewise indistinguishable. Typically both included granulocytes and macrophages, indicating that they were derived from hematopoietic progenitors capable of yielding more than one type of fully differentiated cell.
To check whether the HAT-resistant colonies obtained in these experiments were truly the result of correction of their mutant Hprt genes by homologous recombination in the predicted manner, we devised a RT-PCR assay that amplifies a recombinant RNA fragment that is present only in cells in which the mutation has been corrected in the predicted manner. The assay uses one primer that hybridizes to sequences in exon 1 of the human HPRT gene, which is present in the correcting DNA but not in the mouse BM cells. The other primer hybridizes to exon 4 of the mouse Hprt gene, which is present in the target mouse BM cells but not in the correcting DNA. Thus, specific PCR amplification can occur only when a human/mouse chimeric mRNA is synthesized after the juxtaposition of human exon 1 and mouse exon 4 as a result of homologous recombination at the Hprt genomic locus. The size of the PCR product should be 402 bp. The ethidium bromide-stained gel illustrated in Fig. 2B shows that the recombinant RNA fragment is present in HAT-resistant colonies resulting from correction of the Hprt Ϫ mutation, as judged by the predicted 402-bp PCR product, but is absent in noncorrected Hprt Ϫ cells. The recombinant RNA is also absent in normal Hprt ϩ control cells that synthesize Hprt mRNA having only mouse sequences (data not shown). Confirmation of the RT-PCR result was obtained by sequencing the chimeric 402-bp PCR product by using a primer corresponding to mouse exon 4 (Fig. 2C) . The nucleotide sequence of exon 1 of the PCR product was human (the relevant positions are underlined); the nucleotide sequence of its exon 2 was mouse.
ES cells generally are recognized as efficient in homologous recombination. To serve as a comparative standard for the frequency of recombination in the BM CFCs, we therefore assayed the frequency of gene correction in HM-1 ES cells (9) , which carry the same mutation as the Hprt Ϫ donor mice. The bottom three lines of Table 1 list the correction frequencies in HM-1 cells by using the same correcting DNA as in the BM experiments but with electroporation conditions optimized for ES cells. The average frequency of gene correction was 2.3 Ϯ 0.4 ϫ 10 Ϫ5 , which is not significantly different from that observed in the BM CFCs, 4.4 Ϯ 3.3 ϫ 10 Ϫ5 . We conclude that clonogenic hematopoietic progenitor cells are capable of mediating homologous recombination at a frequency comparable to that seen in ES cells.
Discussion
This demonstration of gene correction by homologous recombination in hematopoietic progenitor cells opens the way to correcting cells of this category with a view to gene therapy that provides short-term hematopoietic support (13) . It also should encourage investigators to approach the task of achieving targeted gene correction in the more primitive HSCs that are capable of populating BM long term. We recognize that our currently demonstrated frequency of gene correction in hematopoietic CFCs is low. We also recognize that, although the exact numbers are debatable, HSCs represent a smaller fraction of BM cells than do the CFCs that we have corrected (which occur at a frequency of approximately two per 10 3 nucleated BM cells). Assays for HSCs are based on their capacity to provide long-term Fig. 1 A. † Number determined directly by a clonogenic assay without HAT selection. ‡ Means Ϯ standard deviation. hematopoietic repopulation in recipient animals, and estimates of their numbers depend on the assay system used. Assays in which marrow cells are transplanted into lethally irradiated recipients (14) suggest a frequency of approximately one HSC per 10 5 nucleated BM cells, whereas those using lethally irradiated wild-type recipients also receiving short-term populating cells (15) or sublethally irradiated (16) and nonirradiated recipients (17) whose endogenous HSCs are genetically handicapped suggest a higher frequency (approximately one per 10 4 nucleated BM cells). These differences probably reflect the effects of radiation damage to the BM microenvironment (18) , so that the higher estimate (one HSC per 10 4 marrow cells) is more applicable to the present discussion. In this case, if HSCs are corrected at the same frequency as CFCs (approximately one event per 2 ϫ 10 4 cells), an average of 2 ϫ 10 8 cells would be required for a single HSC correction event to be detected, which is approximately the number of marrow cells obtainable from four mice. This number of cells could not be injected into a single recipient mouse, and so some form of enrichment for stem cells would be desirable, such as the use of commercially available antibodycoated magnetic beads to discard the majority of unwanted cells but retain a subfraction that includes HSCs.
Our optimism with regard to the feasibility of gene correction in HSCs is supported by the fact that electroporation is versatile and applicable to a wide variety of cell types (19) . Moreover, the overall effectiveness of gene correction in HSCs is open to substantial improvements by modifying various parts of our experimental procedure. First, by doubling the length of the homologous sequences in the input DNA, the targeting frequency can be increased more than 10-fold (20) . Second, the proportion of repopulating HSCs in the BM can be increased at least 10-fold by pretreatment with suitable cytokines (21) . Third, additional genetic material can be introduced into the target locus at the time the HSCs are corrected to provide them with an advantage in engraftment and/or enhance their proliferation in vivo. For example, a transgene encoding a truncated erythropoietin receptor sensitive to exogenously administered erythropoietin is a demonstrated example of such a benign advantage sequence (22) . A transgene encoding a chimeric protein that dimerizes and induces cell growth when exposed to a chemical inducer of dimerization is another example (23) . Predicting the overall improvement in the effectiveness of HSC gene correction achievable by these strategies alone or in combination is difficult, but an improvement of more than 2 orders of magnitude is conceivable. Finally, it appears reasonable to expect that the long-sought goal of expanding HSCs ex vivo (24) eventually will be reached.
Whereas our optimism of achieving gene correction in HSCs at a usable frequency may be justified, there are still serious obstacles to consider. For example, therapeutic gene targeting in human subjects presents problems of genetic heterogeneity that are not observed in isogeneic experimental mice. Additionally, targeting at the Hprt locus occurs at a relatively high frequency and automatically provides a selectable marker for targeted cells; the frequency of targeting at therapeutically more important loci is likely to be less, and direct selection of corrected cells will not usually be possible. Our experiments are nonetheless encouraging because they clearly demonstrate that gene correction by homologous recombination can be achieved in clonogenic progenitor cells, which are in the same lineage as HSCs capable of long-term BM engraftment.
